MSB Trading 2021 - paradigm shift, page-8242

Actually, the changes since the last update, from August 2020, are pretty limited. And while technically it is a "delay" moving primary competion to January 2022, from the previously anticipated November 2021, it is in fact good news. In August 2020 they anticipated primary completion in about 15 months. Now, everyone knows trials everywhere were slowed down by the pandemic. So some sort of delay is to be expected. But now they are estimating primary completion just 3 months from now (only 2 months later than expected over a year ago).

This tells us they are nearing completion of enrollment. That is a good thing!

And although final study completion is extended to 2 years beyond primary completion, that is just to allow 2 years of safety data. They still expect efficacy to be evaluated after 1 year.

https://clinicaltrials.gov/ct2/history/NCT03079401?A=7&B=8&C=merged#StudyPageTop